258 related articles for article (PubMed ID: 31651716)
1. Antibodies Against ARHGDIB and ARHGDIB Gene Expression Associate With Kidney Allograft Outcome.
Senev A; Otten HG; Kamburova EG; Callemeyn J; Lerut E; Van Sandt V; Kuypers D; Emonds MP; Naesens M
Transplantation; 2020 Jul; 104(7):1462-1471. PubMed ID: 31651716
[TBL] [Abstract][Full Text] [Related]
2. ARHGDIB and AT1R autoantibodies are differentially related to the development and presence of chronic antibody-mediated rejection and fibrosis in kidney allografts.
Betjes MGH; Sablik KA; Litjens NHR; Otten HG; de Weerd AE
Hum Immunol; 2021 Feb; 82(2):89-96. PubMed ID: 33358038
[TBL] [Abstract][Full Text] [Related]
3. Antibodies against ARHGDIB are associated with long-term kidney graft loss.
Kamburova EG; Gruijters ML; Kardol-Hoefnagel T; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Melchers RCA; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Bemelman FJ; Otten HG
Am J Transplant; 2019 Dec; 19(12):3335-3344. PubMed ID: 31194283
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
5. Eplet mismatch analysis and allograft outcome across racially diverse groups in a pediatric transplant cohort: a single-center analysis.
Philogene MC; Amin A; Zhou S; Charnaya O; Vega R; Desai N; Neu AM; Pruette CS
Pediatr Nephrol; 2020 Jan; 35(1):83-94. PubMed ID: 31599339
[TBL] [Abstract][Full Text] [Related]
6. Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.
Lefaucheur C; Viglietti D; Bouatou Y; Philippe A; Pievani D; Aubert O; Duong Van Huyen JP; Taupin JL; Glotz D; Legendre C; Loupy A; Halloran PF; Dragun D
Kidney Int; 2019 Jul; 96(1):189-201. PubMed ID: 31005275
[TBL] [Abstract][Full Text] [Related]
7. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
Cuevas E; Arreola-Guerra JM; Hernández-Méndez EA; Salcedo I; Castelán N; Uribe-Uribe NO; Vilatobá M; Contreras-Saldívar AG; Sánchez-Cedillo AI; Ramírez JB; de Rungs D; Granados J; Morales-Buenrostro LE; Alberú J
Nephrol Dial Transplant; 2016 Oct; 31(10):1738-45. PubMed ID: 27220757
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
Zecher D; Bach C; Staudner C; Böger CA; Bergler T; Banas B; Spriewald BM
Nephrol Dial Transplant; 2017 Apr; 32(4):730-737. PubMed ID: 28339671
[TBL] [Abstract][Full Text] [Related]
9. Pretransplant C3d-Fixing Donor-Specific Anti-HLA Antibodies Are Not Associated with Increased Risk for Kidney Graft Failure.
Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma AJ; van der Boog PJM; de Fijter JW; Betjes MGH; Heidt S; Roelen DL; Claas FH; Otten HG
J Am Soc Nephrol; 2018 Sep; 29(9):2279-2285. PubMed ID: 30049681
[No Abstract] [Full Text] [Related]
10. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies?
Irure J; López-Hoyos M; Rodrigo E; Gómez-Román J; Ruiz JC; Arias M; San Segundo D
Transplant Proc; 2016 Nov; 48(9):2888-2890. PubMed ID: 27932099
[TBL] [Abstract][Full Text] [Related]
11. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
Kwon H; Kim YH; Choi JY; Shin S; Jung JH; Park SK; Han DJ
Clin Transplant; 2018 Jun; 32(6):e13266. PubMed ID: 29676812
[TBL] [Abstract][Full Text] [Related]
12. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies.
Amico P; Hönger G; Bielmann D; Lutz D; Garzoni D; Steiger J; Mihatsch MJ; Dragun D; Schaub S
Transplantation; 2008 Jun; 85(11):1557-63. PubMed ID: 18551059
[TBL] [Abstract][Full Text] [Related]
13. Donor-specific B Cell Memory in Alloimmunized Kidney Transplant Recipients: First Clinical Application of a Novel Method.
Wehmeier C; Karahan GE; Krop J; de Vaal Y; Langerak-Langerak J; Binet I; Schaub S; Roelen DL; Claas FHJ; Heidt S;
Transplantation; 2020 May; 104(5):1026-1032. PubMed ID: 31397804
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients.
Lee H; Min JW; Kim JI; Moon IS; Park KH; Yang CW; Chung BH; Oh EJ
Medicine (Baltimore); 2016 Mar; 95(11):e3094. PubMed ID: 26986147
[TBL] [Abstract][Full Text] [Related]
15. Clinical Impact of Pre-transplant Antibodies Against Angiotensin II Type I Receptor and Major Histocompatibility Complex Class I-Related Chain A in Kidney Transplant Patients.
Min JW; Lee H; Choi BS; Park CW; Yang CW; Kim YS; Choi YJ; Oh EJ; Chung BH
Ann Lab Med; 2018 Sep; 38(5):450-457. PubMed ID: 29797816
[TBL] [Abstract][Full Text] [Related]
16. Post-transplant donor specific antibody is associated with poor kidney transplant outcomes only when combined with both T-cell-mediated rejection and non-adherence.
Cherukuri A; Mehta R; Sharma A; Sood P; Zeevi A; Tevar AD; Rothstein DM; Hariharan S
Kidney Int; 2019 Jul; 96(1):202-213. PubMed ID: 31029504
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Serum Angiotensin II Type 1 Receptor Antibodies at the Time of Renal Allograft Rejection.
Lee H; Kim JI; Moon IS; Chung BH; Yang CW; Kim Y; Han K; Oh EJ
Ann Lab Med; 2015 May; 35(3):314-20. PubMed ID: 25932439
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies.
Callemeyn J; Lerut E; de Loor H; Arijs I; Thaunat O; Koenig A; Meas-Yedid V; Olivo-Marin JC; Halloran P; Chang J; Thorrez L; Kuypers D; Sprangers B; Van Lommel L; Schuit F; Essig M; Gwinner W; Anglicheau D; Marquet P; Naesens M
J Am Soc Nephrol; 2020 Sep; 31(9):2168-2183. PubMed ID: 32641395
[TBL] [Abstract][Full Text] [Related]
19. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: Clinical presentation and implications for outcome.
Senev A; Coemans M; Lerut E; Van Sandt V; Daniëls L; Kuypers D; Sprangers B; Emonds MP; Naesens M
Am J Transplant; 2019 Mar; 19(3):763-780. PubMed ID: 30107078
[TBL] [Abstract][Full Text] [Related]
20. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
